Nutritional Epidemiology Institute and School of Public Health, Tianjin Medical University, Tianjin, China.
Department of Clinical Sciences, Lund University, Jan Waldenströms gata 35, CRC, hus 60 plan 13, 205 02, Malmö, Sweden.
Diabetologia. 2019 Jan;62(1):78-86. doi: 10.1007/s00125-018-4751-7. Epub 2018 Oct 22.
AIMS/HYPOTHESIS: Growth differentiation factor 15 (GDF-15) is an anti-inflammatory cytokine of the transforming growth factor-β superfamily. Circulating levels of GDF-15 are associated with hyperglycaemia among people with obesity or diabetes, but longitudinal evidence on the association between GDF-15 levels and diabetes risk is scarce. Our aim was to explore whether circulating levels of GDF-15 at baseline are positively associated with future diabetes incidence in a middle-aged urban population.
Between 1991 and 1994, baseline fasting plasma GDF-15 levels were measured in 4360 individuals without diabetes (mean age 57.4 ± 5.96 years, 38.6% men) who were participants in the Malmö Diet and Cancer-Cardiovascular Cohort. After a follow-up of 19.0 ± 5.16 years (mean ± SD), Cox proportional hazards regression analysis was used for the study of the relationship between baseline GDF-15 and incident diabetes, with adjustment for established confounders. A sensitivity analysis included further adjustment for levels of C-reactive protein (CRP).
During the follow-up period, 621 individuals developed diabetes. The multivariate-adjusted HR for diabetes incidence was 1.43 (95% CI 1.11, 1.83; p for trend = 0.007) for the fourth compared with the first quartile of GDF-15, and was 1.17 (95% CI 1.07, 1.28; p < 0.001) per SD increase of GDF-15. If participants were grouped according to baseline fasting glucose, the association between GDF-15 and diabetes risk was only evident in the group without impaired fasting glucose (n = 3973). The association tended to be less significant with increasing age: multivariate-adjusted HRs for diabetes per SD increase of GDF-15 were 1.24 (95% CI 1.08, 1.42), 1.19 (95% CI 1.00, 1.41) and 1.04 (95% CI 0.89, 1.23) for participants aged ≤55, 56-60 (>55 and ≤60) and >60 years, respectively. With adjustment for levels of CRP, the HR per SD increase of GDF-15 (1.21, 95% CI 1.09, 1.35) was significant (p = 0.015), but the HR for the fourth compared with the first quartile of GDF-15 was not significant (HR 1.30; 95% CI 1.01, 1.67; p for trend = 0.061).
CONCLUSIONS/INTERPRETATION: GDF-15 may be useful for identification of people with a risk of incident diabetes, especially if those people are ≤60 years old.
目的/假设:生长分化因子 15(GDF-15)是转化生长因子-β超家族的一种抗炎细胞因子。循环中的 GDF-15 水平与肥胖或糖尿病患者的高血糖有关,但关于 GDF-15 水平与糖尿病风险之间的纵向证据很少。我们的目的是探讨在中年人群中,基线时循环 GDF-15 水平是否与未来糖尿病的发病率呈正相关。
1991 年至 1994 年间,在无糖尿病的 4360 名参与者(平均年龄 57.4±5.96 岁,38.6%为男性)中测量了空腹血浆 GDF-15 水平,这些参与者是马尔默饮食与癌症-心血管队列的一部分。在随访 19.0±5.16 年后(平均值±标准差),使用 Cox 比例风险回归分析研究了基线 GDF-15 与新发糖尿病之间的关系,并对已确定的混杂因素进行了调整。敏感性分析包括进一步调整 C 反应蛋白(CRP)水平。
在随访期间,621 人发生了糖尿病。与第 1 四分位相比,第 4 四分位的糖尿病发病率的多变量调整 HR 为 1.43(95%CI 1.11,1.83;趋势 p 值=0.007),GDF-15 每增加 1 个标准差的 HR 为 1.17(95%CI 1.07,1.28;p<0.001)。如果根据基线空腹血糖对参与者进行分组,则 GDF-15 与糖尿病风险之间的关联仅在无空腹血糖受损的组中明显(n=3973)。随着年龄的增加,关联的显著性降低:GDF-15 每增加 1 个标准差的糖尿病多变量调整 HR 分别为 1.24(95%CI 1.08,1.42)、1.19(95%CI 1.00,1.41)和 1.04(95%CI 0.89,1.23),分别为≤55 岁、56-60 岁(>55 岁和≤60 岁)和>60 岁的参与者。在调整 CRP 水平后,GDF-15 每增加 1 个标准差的 HR(1.21,95%CI 1.09,1.35)仍具有显著性(p=0.015),但与第 4 四分位相比,GDF-15 第 1 四分位的 HR 不具有显著性(HR 1.30;95%CI 1.01,1.67;趋势 p 值=0.061)。
结论/解释:GDF-15 可能有助于识别有新发糖尿病风险的人群,尤其是年龄≤60 岁的人群。